• If you could be any other CEO, who would you be? Friday, 16 Jan 2015 | 12:14 PM ET
    Tesla Motors CEO Elon Musk speaking in Detroit, January 13, 2015.

    At the J.P. Morgan Healthcare Conference, executives name the CEOs they'd most like to replace.

  • LONDON, Jan 16- GlaxoSmithKline is feeling the heat from the rapid growth in electronic cigarettes, with enthusiasm for the nicotine delivery devices dampening sales of the British drugmaker's patches and gum, its chief executive said. In an interview with Reuters, Andrew Witty also said he and his team had spent "a few days" exploring whether the drugmaker...

  • *Consumer more tenable as standalone business after Novartis deal. Chief Executive Andrew Witty told Reuters the group's large consumer health business would be more viable as a standalone operation following the conclusion of a $20 billion asset swap with Novartis, especially if it bought additional assets. "Post- Novartis, particularly if we did more...

  • SAN FRANCISCO/ WASHINGTON Jan 15- U.S. healthcare executives say Obamacare is likely here to stay, despite repeated calls from Republican lawmakers for repeal of the 2010 law aimed at providing health coverage for millions of uninsured Americans. Top executives who gathered in San Francisco this week for the annual J.P. Morgan Healthcare conference, say that...

  • *Asset could be worth up to 2 bln euros- Bloomberg. FRANKFURT, Jan 15- German drugmaker Boehringer Ingelheim said it is considering the sale of its U.S.-based generics unit Roxane Labs to put a stronger focus on the development and sale of new pharmaceuticals. A company spokeswoman said Boehringer was not a specialist in generics and was therefore considering...

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....

  • Jan 14- German drugmaker Boehringer Ingelheim is considering the sale of its U.S. generics unit Roxane Labs for as much as 2 billion euros, Bloomberg said, citing people with knowledge of the matter. Boehringer Ingelheim officials were not immediately available for comment outside office hours. The drugmaker is working with Morgan Stanley on the sale, two of the...

  • SAN FRANCISCO, Jan 14- Silicon Valley- based genetic testing company 23 andMe is looking for new growth of its direct-to-consumer DNA tests abroad, building on recent expansions into Canada and the UK. Neither Canada or the UK required premarket approval for distributing its tests, the company said. Since the FDA decision, the company has continued to sell...

  • Biopharma's challenges in 2015  Wednesday, 14 Jan 2015 | 9:30 AM ET

    Biopharma executives at the J.P. Morgan Healthcare Conference talk about this year's biggest challenges.

  • Navellier’s crunching finds growth for cheap Wednesday, 14 Jan 2015 | 6:00 AM ET
    Actavis Group headquarters is shown in Hafnarfjordur, Iceland, April 20, 2006.

    Louis Navellier says crunching the numbers for stocks that move independent of the market point him to two drug companies and a Chinese retailer.

  • Juno's promising CAR-T immunotherapy  Tuesday, 13 Jan 2015 | 5:15 PM ET

    Hans Bishop, Juno Therapeutics co-founder and CEO, discusses promising data for new cancer immunotherapy approaches.

  • CEO: 2015 exciting for Vertex  Tuesday, 13 Jan 2015 | 3:10 PM ET

    Vertex CEO Dr. Jeffrey Leiden tells CNBC's Meg Tirrell about the company's new drug trials and focus areas in 2015.

  • Orexigen CEO: Excited about obesity drug progress  Tuesday, 13 Jan 2015 | 2:22 PM ET

    Mike Narachi, Orexigen CEO, speaks with CNBC's Meg Tirrell about its obesity drug and program.

  • Ariad CEO: Expanding Iclusig  Tuesday, 13 Jan 2015 | 1:47 PM ET

    Ariad CEO Harvey Berger, tells CNBC's Meg Tirrell commercially the company had a good year and provides insight into its new cancer drug, Iclusig.

  • Chimerix tackles Ebola outbreak  Tuesday, 13 Jan 2015 | 11:46 AM ET

    Michelle Berrey, Chimerix CEO, discusses the testing of its Ebola drug Brincidofovir in a clinical setting in West Africa, with CNBC's Meg Tirrell.

  • Cigna's expansion strategy  Tuesday, 13 Jan 2015 | 10:17 AM ET

    David Cordani, Cigna president & CEO, weighs in on rival Aetna's wage plan and explains Cigna's growth strategy.

  • SAN FRANCISCO, Jan 12- Eli Lilly and Co said on Monday that U.S. insurers are increasing pressure on the price of diabetes medications as they switch coverage from certain drugs to others to trim costs. "We've definitely seen increased price competition, more by payers than the companies themselves," Lilly Chief Financial Officer Derica Rice said on Monday in an...

  • J&J CEO: Too early to fully assess Obamacare  Monday, 12 Jan 2015 | 5:43 PM ET

    Alex Gorsky, Johnson & Johnson chairman and CEO, discusses how the ACA and the recovery in the economy is impacting business.

  • Shire CEO: $5.2 billion NPS deal will pay off  Monday, 12 Jan 2015 | 5:16 PM ET

    Flemming Ornskov, Shire CEO, tells CNBC's Meg TIrrell it is the right time for the proposed acquisition of NPS Pharmaceuticals.

  • Merck CEO: Deals create value  Monday, 12 Jan 2015 | 4:27 PM ET

    Merck CEO Ken Frazier plans to focus on its specialized area strategy in 2015, with CNCB's Meg Tirrell.